Rituximab vs Sars-Cov-2 Virus Spike Protein

## Rituximab vs Sars-Cov-2 Virus Spike Protein: Overview

This comparison examines the pharmacological differences between **Rituximab** and **Sars-Cov-2 Virus Spike Protein**.

## Mechanism of Action

**Rituximab**: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

## Pharmacokinetics

**Half-life**: Rituximab — 22 days; Sars-Cov-2 Virus Spike Protein — N/A.

## Chemical Properties

**Type**: Rituximab — Antibody; Sars-Cov-2 Virus Spike Protein — Vaccine component.